ERBB2 and colorectal cancer: Fruquintinib was approved for late-line treatment and an HER2-targeted therapy, tucatinib plus trastuzumab [39], received FDA accelerated approval in early 2023, providing a new treatment option for HER2-positive colorectal cancer patients.